KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) Return on Equity (2016 - 2025)

Historic Return on Equity for Arbutus Biopharma (ABUS) over the last 15 years, with Q3 2025 value amounting to 0.53%.

  • Arbutus Biopharma's Return on Equity rose 1400.0% to 0.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.53%, marking a year-over-year increase of 1400.0%. This contributed to the annual value of 0.69% for FY2024, which is 900.0% down from last year.
  • According to the latest figures from Q3 2025, Arbutus Biopharma's Return on Equity is 0.53%, which was up 1400.0% from 0.67% recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Return on Equity peaked at 0.44% during Q2 2022, and registered a low of 0.87% during Q1 2025.
  • Moreover, its 5-year median value for Return on Equity was 0.61% (2021), whereas its average is 0.59%.
  • Its Return on Equity has fluctuated over the past 5 years, first skyrocketed by 13600bps in 2021, then plummeted by -1900bps in 2025.
  • Over the past 5 years, Arbutus Biopharma's Return on Equity (Quarter) stood at 0.51% in 2021, then rose by 3bps to 0.49% in 2022, then plummeted by -31bps to 0.65% in 2023, then decreased by -6bps to 0.68% in 2024, then grew by 23bps to 0.53% in 2025.
  • Its Return on Equity was 0.53% in Q3 2025, compared to 0.67% in Q2 2025 and 0.87% in Q1 2025.